Why Nanox Stock Lost Almost 30% in December

Shares of Nano-X Imaging (NASDAQ: NNOX), commonly referred to as Nanox, fell 29.5% in December, according to data provided by S&P Global Market Intelligence. The company did get Food and Drug Administration (FDA) clearance in December, but not the one investors were hoping for, which might explain the stock's underperformance for the month. Nanox plans to commercialize a medical device called the multi-source Nanox.ARC, which can quickly and cheaply make a digital X-ray.